Systemic Therapy for Hepatocellular Carcinoma.
作者信息
Wang Jennifer, Pillai Anjana
机构信息
Division of Gastroenterology, Hepatology, and Nutrition Department of Internal Medicine University of Chicago Medicine Chicago IL.
出版信息
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):337-340. doi: 10.1002/cld.1058. eCollection 2021 May.
Abstract
摘要
相似文献
1
Systemic Therapy for Hepatocellular Carcinoma.肝细胞癌的全身治疗
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):337-340. doi: 10.1002/cld.1058. eCollection 2021 May.
2
Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.使用携带羧肽酶G2的靶向腺病毒对肝细胞癌进行全身基因导向酶前药治疗。
Cancer Res. 2005 Jun 15;65(12):5003-8. doi: 10.1158/0008-5472.CAN-05-0393.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
[Systemic chemotherapy of hepatocellular carcinoma].[肝细胞癌的全身化疗]
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1584-8.
5
Battle Royale: Systemic Versus Locoregional Therapy for Unresectable Hepatocellular Carcinoma.《大逃杀：不可切除肝细胞癌的系统治疗与局部区域治疗》。
AJR Am J Roentgenol. 2018 Jun;210(6):1366-1367. doi: 10.2214/AJR.17.19392. Epub 2018 Apr 18.
6
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.全身治疗在肝细胞癌中的作用及未来方向
Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243.
7
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside.肝细胞癌（HCC）的系统治疗：从实验台到病床边
J Egypt Natl Canc Inst. 2013 Dec;25(4):165-71. doi: 10.1016/j.jnci.2013.08.002. Epub 2013 Sep 21.
8
[Hepatocellular carcinoma].[肝细胞癌]
Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23.
9
Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.原发性肝细胞癌患者的肿瘤分期及初始治疗方式分布
Clin Transl Oncol. 2017 Jul;19(7):891-897. doi: 10.1007/s12094-017-1621-6. Epub 2017 Feb 3.
10
Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.肝细胞癌抗血管生成治疗的临床试验
Int J Clin Oncol. 2016 Apr;21(2):213-218. doi: 10.1007/s10147-016-0966-0. Epub 2016 Feb 22.
引用本文的文献
1
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.在二线使用瑞戈非尼或免疫检查点抑制剂治疗期间，局部区域治疗可提高肝癌患者的总生存率。
Am J Cancer Res. 2024 Mar 15;14(3):1306-1315. doi: 10.62347/GFVP1262. eCollection 2024.
2
Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview.失代偿期肝硬化患者肝细胞癌的管理：全面概述
Cancers (Basel). 2023 Feb 18;15(4):1310. doi: 10.3390/cancers15041310.
3
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma.硝唑尼特通过胰岛素样生长因子1受体（IGF-1R）/干性及代谢变化使索拉非尼在肝细胞癌中恢复活力
Cancers (Basel). 2023 Feb 1;15(3):931. doi: 10.3390/cancers15030931.
4
Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma.免疫疗法在肝癌患者肝移植前的应用。
Curr Oncol. 2022 Dec 13;29(12):9813-9825. doi: 10.3390/curroncol29120771.
本文引用的文献
1
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
2
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
3
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
4
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
5
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
6
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
7
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
8
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
9
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.肝细胞癌的诊断、分期及管理：美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
10
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
Zotero 插件